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ABSTRACT 
 Vitiligo is described as an autoimmune-mediated skin disorder in which 
melanocytes are targeted and killed by cytotoxic lymphocytes, resulting in 
depigmentation of the skin. One cause of vitiligo progression is when stressed or damaged 
melanocytes release a 70kDa stress-induced heat shock protein (HSP70i) carrying 
melanocyte protein; this activates nearby dendritic cells toward an inflammatory 
phenotype which circulate through the lymph and prime a cytotoxic response against 
melanocyte antigen. The Le Poole lab previously identified a peptide within HSP70i 
responsible for activating this inflammatory phenotype in human DCs and developed 
HSP70iQ435A. It was found that treatment with HSP70iQ435A is able to prevent proliferation 
of the vitiligo-associated inflammatory DC phenotype, thus preventing accumulation of 
melanocyte antigen-specific T cells in the skin and reducing depigmentation in mice.  
However, because treatment with HSP70iQ435A inhibits this DC-mediated auto-
immune response against melanocytes in vitiligo mouse models, there existed a valid 
concern that treatment with this modified heat shock protein may also inhibit natural 
anti-tumor responses against melanocyte-derived melanoma tumor cells. Therefore, the 
first hypothesis of this project is that HSP70iQ435A prevents migration of melanocyte-
antigen reactive T cells to the skin in a way that is mechanistically different from anti-
tumor responses to melanoma and therefore would not have a negative effect on anti-
viii 
tumor responses. Using data gathered from testing this first hypothesis, a second 
hypothesis was established, proposing that treatment with HSP70iQ435A confers anti-
melanoma resistance through antibody-dependent cell-mediated cytoxicity. 
To test the first hypothesis, BL/6 mice were treated with DNA-vaccines encoding 
WT HSP70i, HSP70iQ435A, or were not vaccinated for 5 weeks and then tumor-challenged 
with B16 mouse melanoma. Results from several of these vaccination/tumor-challenge 
mouse experiments displayed that treatment with both WT HSP70i and HSP70iQ435A 
inhibit tumor growth in the subsequent tumor challenge when compared to the non-
vaccinated mice. CD3 T cell migration to the melanoma was not negatively affected in the 
treated mice. Surface staining of B16 melanoma cells also revealed surface expression of 
HSP70i, consistent with past observations of tumor cell overexpression and surface 
expression of heat shock proteins. These data suggest that anti-tumor responses 
following treatment with HSP70iQ435A are not inhibited but actually strengthened, and this 
anti-tumor response may be related to the overexpression of HSP70i common to tumor 
cells.  
To test the second hypothesis, B-Cells were adoptively transferred from HSP70i 
DNA-vaccinated BL/6 mice into naïve BL/6 that then received a tumor challenge. Results 
displayed that mice receiving the adoptively transferred B cells had decreased tumor 
growth rates and final tumor mass, when compared to tumor-challenged mice that did 
not receive adoptively transferred cells. Furthermore, serum taken from vaccinated 
animals (mouse and swine) show increased levels of anti-HSP70i antibody. Taken 
together, these data suggest that HSP70iQ435A polarizes dendritic cells to support 
ix 
antibody-mediated responses to surface HSP70i expressed by tumor cells while 
preventing migration of melanocyte-antigen reactive T cells to the skin. 
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CHAPTER 1 
INTRODUCTION 
Vitiligo Background 
Vitiligo is described as an autoimmune-mediated skin disorder in which 
melanocytes are killed, resulting in depigmentation of the skin. During vitiligo, 
melanocytes are destroyed by melanocyte-reactive T cells, as well as other immune or 
non-immune components (1). Expanding vitiligo lesions are consistently infiltrated with T 
cells in the areas lining the lesional borders; these infiltrating T cells are composed 
primarily of CD8+ cytotoxic T cells reactive with melanocyte-specific antigens (2). 
Moreover, increased numbers of inflammatory CD11c+ dendritic cells have been 
observed in the lesional skin of vitiligo patients, which are thought to lend to the increased 
auto-immune response leading to vitiligo (3).  
However, problems arise in the development of effective therapeutics for the 
disease because re-establishing pigmentation in patients with active disease would likely 
be problematic without first halting progression of the disease; in this sense, 
understanding the cellular mechanisms behind depigmentation in vitiligo disease became 
a key focus of vitiligo studies.  
Previous research into the mechanisms behind vitiligo progression has 
demonstrated a link between stress-induced heat shock proteins as players involved in 
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the autoimmune responses responsible for vitiligo (5). Primary among these immune-
activating stress proteins are HSPs 60, 70, and 90 (5). Certain HSPs assist in normal cellular 
functions such as protein-misfold repair; others are synthesized only under stress (12). Of 
interest among these stress-inducible HSPs is an inducible form of Heat Shock Protein 70 
(HSP70i, also known as HSP72) which is known to be secreted from live cells through an 
active-release mechanism (9). Under standard physiological conditions, the constitutive 
isoform of HSP70 (HSC70) is expressed within the cell offering cytoprotection to the cell 
through assisting in chaperoning misfolded proteins. However, through cell death or 
active secretion, an inducible isoform of HSP70 (HSP70i) can be released into the 
extracellular environment where it is then able to interact with dendritic cells to enhance 
the uptake of antigens (7). This implies that an auto-immune response to HSP70i, and any 
proteins it may be chaperoning, can occur even in the absence of cell death.  
HSP70 and Vitiligo 
In vitro studies have associated HSP70 as a factor in the formation of the vitiligo 
disease state: melanocytes were shown to overexpress HSP70 in response to the 
bleaching agent 4-tertiary butyl phenol (4-TBP), a compound used in rubber manufacture 
and the photoindustry, which is selectively cytotoxic to melanocytes within the skin and 
induces depigmentation in vitiligo patients sensitive to these agents (3). Increased 
amounts of HSP70 were detectable in the supernatant of vitiligo melanocytes compared 
to control melanocytes (3). Studies comparing the lesional and non-lesional skin of three 
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vitiligo patients show consistent differential expression of HSP70 as observed by 
immunohistological staining, further implying that HSP70 plays a role for in autoimmune-
induced depigmentation of melanocytes (8).  
HSP70iQ435A 
Previously, the Le Poole lab identified a peptide within the stress-inducible HSP70i 
responsible for activating human dendritic cells and developed HSP70iQ435A, a mutant 
DNA isoform with a single amino acid modification. Located on the outer cusp of the 
substrate binding domain in 3D models of the protein, just outside the substrate binding 
groove, this change in amino acid 435 affects activation of DCs following binding with the 
stress protein. It was found that vaccination with this mutant form of HSP70 
(HSP70iQ435A) is able to prevent proliferation of the vitiligo-associated inflammatory 
dendritic cell phenotype, thus preventing accumulation of melanocyte antigen-specific T 
cells in the skin and reducing depigmentation in mice (4). These findings suggested that 
the mutant form HSP70i is not only an inactive variant but also binds DCs and alters their 
function in such a way that interferes with later T cell activation. The implications of this 
study are that HSP70iQ435A DNA delivery may be used for the treatment of vitiligo (4).  
Melanoma Background 
While vitiligo deals with melanocyte death, at the other end of the spectrum we 
have the uncontrollable proliferation of melanocytes in the form of melanoma skin 
cancer. Skin cancer, the current most common malignancy across the world, is often 
classified as either non-melanoma skin cancer (NMSC) or melanoma skin cancer (14). 
4 
 
 
NMSC, which is rarely lethal, accounts for the majority of skin cancer cases, with the most 
common types being basal cell cancer and squamous cell cancer. Malignant melanoma 
skin cancer, while accounting for only ~4% of all skin cancers, is the major cause of death 
from skin cancer (15). Melanoma is derived from pigment-producing melanocytes which, 
within in the skin, are found at the basal level of the epidermis (14). Immune suppression 
in the skin, induction of uncontrolled melanocyte cell division, or DNA damage of growth 
regulatory genes caused by sources such as UV radiation or reactive oxygen species (16) 
all contribute to the development and progression of melanoma. While non-metastatic 
melanoma can be treated with surgical removal if detected early, later stage metastatic 
malignant melanoma is extremely difficult to treat with existing cancer therapies and 
often has a poor prognosis, with a median survival rate of 6 months and a 5-year survival 
rate of less than 5% (15). In 2012, the American Cancer Society reported 1.6 million new 
cases of skin cancer, with about 76,000 of those cases diagnosed as melanoma; of the 
12,190 deaths caused by skin cancer in 2012, almost 9,200 were caused by melanoma 
(14). For a malignant melanoma cell to be successful it must persist in incredibly high-
stress environments; under these difficult conditions, melanoma cells often upregulate 
stress proteins as a means of promoting protein homeostasis and cellular viability (13).  
Link between HSP70i, Vitiligo, and Melanoma 
The overexpression of HSP70i in these tumor cells is often associated with 
secretion and membrane-expression of stress proteins with evidence to suggest that 
HSP70i is one of these stress proteins is that is overexpressed and expressed on the 
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membrane of primary and metastatic melanoma cells but not normal cells; as such, 
HSP70i may be a viable target for anti-melanoma therapeutics (10). This information 
becomes even more exciting when you consider that vitiligo is known to be an 
unavoidable side-effect of certain melanoma therapeutics which target melanoma-
antigen, as there is often crossover between antigen expressed on melanoma cells and 
antigen expressed on melanocytes, resulting in an immune response toward the 
melanoma cell that collaterally attacks healthy melanocytes. With this in mind, there is a 
concern that treatment for vitiligo with this mutant HSP70i may alter the autoimmune 
response in such a way that the immune cells directly affected by HSP70i interaction (DCs, 
T-Cells) would not as effectively target melanoma tumor. 
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HYPOTHESIS 
HSP70iQ435A polarizes dendritic cells to support B cell responses to surface HSP70i 
expressed by tumor cells while preventing migration of melanocyte-antigen reactive T 
cells to the skin. 
 
The following specific aims were established to test the hypothesis. 
 
SPECIFIC AIMS 
 
Aim I: Measure melanoma and vitiligo development in response to HSP70iQ435A 
vaccination. 
These experiments will help shed light on the consequences of HSP70iQ435A  vaccination 
with regards to anti-melanoma immunity, and whether or not tumor containment is 
affected by this change in auto-immunity. 
 
Sub-Aim I: Determine the effect of HSP70iQ435A vaccination on tumor growth without 
eliciting depigmentation. 
Vaccinate WT C57BL/6 mice with HSP70iQ435A and challenge with B16-F10 melanoma 
cells, following tumor growth and depigmentation over time. 
Sub-Aim II: Determine if HSP70iQ435A vaccination is able to inhibit depigmentation in 
vitiligo-prone mice while inhibiting tumor growth. 
Vaccinate PMEL-1 mice and challenge with B16 melanoma cells, following tumor growth 
and depigmentation over time. 
Sub-Aim III: Begin to examine the effects of HSP70iQ435A vaccination in vitiligo-prone 
swine to address the bioavailability, safety, and efficacy of a DNA vaccine designed to 
treat vitiligo. 
 Treat swine vitiligo lesions with DNA vaccine and assess changes in lesional size over 
time. 
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Aim II: Establish the cell(s) responsible for tumor containment and depigmentation. 
These experiments will help us understand the mechanism by which treatments with 
the DNA-vaccines encoding HSP70iQ435A and WT HSP70i are able to promote anti-
melanoma responses in mice. 
 
Sub-Aim I: Examine humoral responses to HSP70i after vaccination with the 
HSP70iQ435A clinical vector. 
Immune monitoring of available serum and relevant tissues from animals after 
HSP70iQ435A vaccination or adoptive transfer. 
Sub-Aim II: Determine which immune cells, if any, are involved in tumor containment 
as a result of HSP70iQ435A vaccination. 
Vaccinate WT C57BL/6 mice with HSP70iQ435A and adoptively transfer immune cells from 
the vaccinated mice to B16-challenged SCID/beige immune-deficient recipient mice. 
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CHAPTER 2 
AIM I: Measure melanoma and vitiligo development  
in response to HSP70iQ435A vaccination. 
 
SUB-AIM I: Determine the effect of HSP70iQ435A vaccination  
on tumor growth without eliciting depigmentation. 
 
EXPERIMENTAL APPROACH 
To prepare the bullets for gene gun vaccination, 100 μg of endotoxin-free plasmid 
DNA of both WT HSP70i and HSP70iQ435A (prepared in pUMVC3 DNA vector, designed by 
the University of Michigan’s Vector Core) was precipitated onto spermidine-coated gold 
micro-particles in the presence of 200mM CaCl2 and washed with 6 volumes of ethanol. 
Washed beads were precipitated onto silicone tubing in a BioRad Tubing Prep Station and 
prep. The DNA-coated tubing was cut into sections that fit the Helios Gene Gun (BioRad), 
with about 1.2 μg of DNA per bullet. Bullets were used within 2 weeks of preparation. 
WT C57BL/6J mice (Jackson Labs, Bar Harbor, ME) were used in this experiment. 
The mice were separated into 3 vaccination groups: control, WT HSP70i, and HSP70iQ435A. 
For each group, n=6. Mice were prepared for gene gun vaccination by biweekly ventral 
hair removal with Nair. The mice were anesthetized using 5% isoflurane and vaccinated 
with four bullets each (4.8 μg of DNA) for five consecutive weeks (one vaccination every 
9 
 
 
 
6 days). During gene gun vaccination with the Helios Gene Gun, gold micro-particles 
coated with DNA are released from silicon tubing cartridges under helium pressure at a 
maximum of 300 p.s.i., which allows for the DNA to directly enter the skin and nestle 
inside relevant cell types such as DC, where the DNA is mechanically transfected and 
expressed. 
One week after the final vaccination, the mice were sub-cutaneously challenged 
with 105 cells of the B16 mouse melanoma cell line; the tumors were injected near the 
sites of vaccination, once in the left flank and once in the right flank of each mouse. Tumor 
progression was followed over the next several weeks using a pair of calipers to 
determine tumor volume in each mouse. Two weeks after the first sign of a palpable 
tumor (which took 8 days to emerge post-injection) the mice were sacrificed; their final 
tumor volumes were measured and the tumors were harvested to be weighed for mass 
and cryopreservation.  
RESULTS 
The experiment outlined in the experimental approach is a repeat of a vaccination 
experiment performed during my initial rotation in the lab; during this initial vaccination 
the mice were vaccinated with WT HSP70 in TOPO 3.1 GFP vector and HSP70iQ435A in TOPO 
3.1 GFP vector (rather than pUMVC3 vector, as described in the previous experimental 
approach section). It was repeated again using the pUMVC3 vector because the pUMVC3 
vector is approved for clinical trials while the TOPO 3.1 vector is not. 
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In the pUMVC3 vector vaccinated mice, tumor progression was followed after the 
first sign of tumor growth (Day 0). When compared to the unvaccinated mice, the 
vaccinated mice displayed a longer onset of tumor growth (by about 3 days), an average 
decreased tumor growth rate as a measure of volume, and smaller tumors on average as 
a measure of volume (66% decrease in final tumor size for the HSP70iQ435A vaccinated 
mice, 62% decrease in final tumor size for the WT HSP70i vaccinated mice).  
 
Figure 1: Tumor Growth is slowed in mice vaccinated with pUMVC3 vector DNA 
encoding WT HSP70i and HSP70iQ435A. 
 
As seen in Figure 1, the difference in combined tumor volume by the end of the 
experiment displayed significance for both vaccination groups (p=0.0143 between 
Control and HSP70iQ435A, p=0.0262 between Control and WT HSP70i). Final tumor volumes 
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were analyzed for significance using an unpaired, two-tailed T-Test with a confidence 
interval of 95%. (n = 6 for each group). 
 
 
Figure 2: Mice vaccinated with pUMVC3 vector DNA encoding HSP70i WT and 
HSP70iQ435A show reduction in average tumor mass. 
 
After sacrifice of the animals, the tumors were harvested, weighed, and the 
average tumor masses per vaccination group were compared. As seen in Figure 2, a 
student’s T-Test revealed a significant 70% decrease in average tumor mass of the 
HSP70iQ435A vaccinated animals when compared to the control animals (p=0.0273), while 
the WT HSP70i vaccinated animals trended toward a smaller average tumor mass than 
the control animals but did not reach significance (p=0.0881). 
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Figure 3: Trend toward decreased melanoma tumor growth seen in mice vaccinated with 
TOPO vector DNA encoding WT HSP70i and HSP70iQ435A. 
 
 
For reference, tumor growth data from the original TOPO vector vaccinated mice 
are included as follows. The vaccinated mice represented in Figure 3 displayed a longer 
onset of tumor growth, an average decreased tumor growth rate as a measure of volume, 
and smaller tumors on average as a measure of volume. The vaccinated mice trended 
towards smaller average tumor volumes when compared with the average tumor volume 
of unvaccinated mice (p=0.1886 between Control and HSP70iQ435A, p=0.1881 between 
Control and WT HSP70i) (n = 5 for each group). 
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Figure 4: Mice vaccinated with both forms of HSP70i in TOPO vector show a trend in 
reduction of tumor mass.  
 
As seen in Figure 4, the difference in both the average tumor mass of the 
HSP70iQ435A vaccinated animals and the average tumor mass of the WT HSP70i vaccinated 
animals trended toward a smaller tumor mass than the tumors of the control animals, but 
did not reach significance (p=0.1765 for the HSP70iQ435A vaccinated animals, p=0.1918 for 
the WT HSP70i vaccinated animals). (n = 5 for each group) 
Together, these data showing significantly decreased tumor growth rates and final 
tumor mass in the vaccinated mice indicate that anti-melanoma responses are not 
inhibited, but strengthened by vaccination with both forms of HSP70i.  
14 
 
 
SUB-AIM II: Determine if HSP70iQ435A vaccination is able to inhibit depigmentation in 
vitiligo-prone mice while inhibiting tumor growth. 
  
EXPERIMENTAL APPROACH 
The mice used in this experiment are transgenic PMEL-1 mice, which carry T cells 
with a rearranged T cell receptor specific for the mouse homologue (pmel-17) of human 
melanocyte protein gp100 and naturally develop vitiligo (11). Prior to vaccination the 
mice were imaged (dorsally and ventrally) using a photo-scanner to measure pre-
vaccination pigmentation. Gene Gun bullet preparation and Gene Gun vaccinations were 
carried out as described in Aim I: Sub-Aim I. Mice were DNA-vaccinated with  either 2.4μg 
of WT HSP70i in pUMVC3 plasmid DNA, or 2.4ug of HSP70iQ435A in pUMVC3 plasmid DNA. 
Due to time constraints, each mouse was also DNA-vaccinated with 2.4ug of hGP100 in 
TOPO plasmid DNA; this was done to facilitate depigmentation. The mice received 5 
vaccinations every 6 days, followed by 2 booster vaccinations 4 days apart. Over the 
course of the vaccinations, the mice were imaged using the photo-scanner immediately 
prior to their biweekly hair-removals. 
One week after the final vaccination, the mice were sub-cutaneously tumor 
challenged with 105 B16 mouse melanoma cells as described in Aim I: Sub-Aim I. Tumor 
progression was followed as a measure of volume while the mice were alive, and 
pigmentation was measured just before sacrifice. Tumors were harvested from the mice 
upon sacrifice and weighed for mass and cryopreservation. Statistical analysis was 
conducted on average final tumor volumes as well as average tumor masses to determine 
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the effect of HSP70i/ HSP70iQ435A on tumor containment. 
Depigmentation/Repigmentation was also be analyzed using scans taken before, during, 
and after treatment.  
RESULTS 
 
Figure 5: Average tumor growth rates from PMEL-1 mice following DNA-vaccinations 
and tumor challenge. 
 
Tumor growth was measured after the first sign of tumor growth in WT HSP70i 
vaccinated mice on Day 12, and Day 13 in HSP70iQ435A vaccinated mice. As seen in Figure 
5, the mice vaccinated with HSP70iQ435A displayed a longer onset of tumor growth and 
smaller tumors on average as a measure of volume when compared to the mice 
vaccinated with WT HSP70i, though not significantly different (n = 10 for each group).  
16 
 
 
 
      
 
Figure 6: Final average tumor mass from PMEL-1 mice following DNA-vaccinations and 
tumor challenge. 
 
As seen in Figure 6, the average final tumor mass of the HSP70iQ435A vaccinated 
mice was 0.8g while the average final tumor mass of the WT HSP70i vaccinated mice was 
1g; the average final tumor mass of the HSP70iQ435A vaccinated mice was decreased, but 
not significantly different when compared to the WT HSP70i vaccinated mice. This data 
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further suggests that tumor containment is not impeded by DNA-vaccination with the 
mutant HSP70iQ435A.  
 
 
Figure 7: Images of PMEL-1 depigmentation over the course of the study. 
 
Figure 7 shows images of mice taken immediately prior to treatment (Week 0) and 
immediately prior to sacrifice (Week 10). Areas of depigmentation can be seen along the 
abdomen where DNA vaccination took place (n = 10 for each group). 
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Figure 8: PMEL-1 average depigmentation over the course of the study might be 
trending toward decreased average depigmentation in HSP70iQ435A vaccinated mice. 
 
Depigmentation was analyzed as a measure of luminosity level change when 
compared to the individual animal’s starting levels measured at 4.22.  As seen in Figure 8 
at the 6.04 time point, the WT HSP70i vaccinated mice display an average of 46% 
depigmentation, while the HSP70iQ435A vaccinated mice display an average of 38% 
depigmentation, a 1.2 fold increase in WT over Q435A. At the 7.08 time point, the WT 
HSP70i vaccinated mice display an average of 55% depigmentation, while the HSP70iQ435A 
vaccinated mice display an average 46% depigmentation, a 1.2 fold increase in WT over 
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Q435A. (n = 10 for each group). These depigmentation data indicate a small decrease in 
depigmentation in the HSP70iQ435A treated mice, but no significant difference.  
 
SUB-AIM III: Begin to examine the effects of HSP70iQ435A vaccination in vitiligo-prone 
swine to address the bioavailability, safety, and efficacy of a DNA vaccine designed to 
treat vitiligo. 
 
Bringing HSP70iQ435A closer to the clinic, our lab plans to introduce and track the 
HSP70iQ435A vaccine in swine with human-like skin and manipulate tumor growth and 
depigmentation in response to wild type and mutant HSP70i in Sinclair swine with 
spontaneous melanomas and vitiligo to  address the microenvironmental signature of 
relevant sites. 
EXPERIMENTAL APPROACH 
Animals were treated weekly with 5 mg of the drug for a total of 4 weeks. A 
PharmaJet injector is being used to deliver 4 doses of 0 (control) or 1.25 mg/mL DNA in 
0.5 mL each to the border of a single, preselected lesion. Animals were followed for 6 
months from the first DNA vaccination. The primary objectives were to measure changes 
in lesional expansion (relative to the injection sites) by biweekly grid measurements and 
to follow drug distribution and local and systemic reactivity over time. Biweekly 50ml 
blood draws will be accompanied by monthly perilesional biopsies under local lidocaine 
anesthesia from treated and untreated perilesional skin before, during, and after 
treatment. For blood sampling and biopsies, pigs are secured and anesthetized with 2-4% 
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isoflurane using a mask.  4 mm biopsies were taken and skin were sutured with Vycril 
sututre or vetbond tissue adhesive, accompanied by topical application of triple antibiotic 
ointment as a preventive measure against infection. Animals were monitored until 
conscious before returning them to their cage, hourly thereafter until the animal 
appeared calm, and every next day until suture removal. Biopsies were snap-frozen on 
dry ice and stored at -80c until needed for cryosectioning and tissue staining. The pigs and 
lesional areas are followed for progressive depigmentation or repigmentation, similar to 
testing planned in human subjects, wherein grid measurements are made to quantify 
lesional area (including both treated and untreated lesions) at 2 week intervals before 
and after vaccination. At euthanasia, major tissues will be collected, screened, and 
evaluated for drug content. Remaining melanoma tumor mass will be measured. Tissues 
collected are stored frozen for further analysis of antibody titers by ELISA, and 
immunostaining to quantify immune infiltrates according to parameters previously 
established in mice [see Aim II: Sub-Aim II results]. 
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RESULTS 
 
 
 
Figure 9: Treatment with DNA-vaccine encoding HSP70iQ435A can induce repigmentation 
of lesional vitiligo in swine. 
 
Lesional areas of interest were measured over the course of the study and changes 
in the vaccination-site lesion are represented in Figure 9. As seen in these data, the DNA 
treated swine in Group #1 displayed a very significant decrease (p = 0.0001) in vitiligo 
lesional area when comparing the starting time point with the final time point, decreasing 
in size 75% over the course of 27 weeks (9a). The Group #1 and group #2 PBS swine 
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showed increasing melanoma lesional size (9b, 9d). The Group #2 DNA treated swine 
displayed a 300% increase in lesional size (9c).  
 
 
  
 
Figure 10: Treatment with DNA-vaccine encoding HSP70iQ435A can induce repigmentation 
of lesional vitiligo in swine. 
 
Figure 10 shows images of treated vitiligo lesions on both of the DNA treated 
swine; the images for the Group #1 swine were taken at Week 1 [10a] and Week 27 [10b] 
while the images for the Group #2 swine were taken at Week 1 [10c] and Week 18 [10d]. 
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The Group #1 swine displayed a significant regression of its vitiligo lesion between Week 
1 [10a] and Week 27 [10b], regressing about 78% from its original size. The Group #2 DNA 
treated swine displayed a 300% increase in lesional size from Week 1 [10c] to Week 18 
[10d]. These data from the DNA vaccinated swine in Group #1 suggest a positive response 
to the drug in terms of vitiligo inhibition and regression.
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CHAPTER 3 
AIM II: Determine the contribution of B cells to tumor containment and depigmentation. 
 
SUB-AIM I: Determine which immune cells, if any, are involved in tumor containment  
as a result of HSP70iQ435A vaccination. 
  
 
From these experiments I am hoping to gain further insight into which immune 
cells are involved in tumor containment following a vaccination with HSP70i/ HSP70iQ435A. 
This involves the transfer of cells from vaccinated mice to naïve, tumor-challenged mice. 
The cells being transferred are CD8+ T-Cells, CD11c+ Dendritic Cells, and B220+ B cells. A 
second adoptive cell transfer experiment involved the transfer of cells from 
HSP70i/HSP70iQ435A vaccinated C57BL/6J mice into tumor-challenged immunodeficient 
SCID-beige mice. SCID-beige mice were used due to their lack of a functional immune 
system which can help decipher whether an individual cell type is soley responsible for 
anti-tumor protection during the adoptive cell transfer.  
EXPERIMENTAL APPROACH 
WT C57BL/6J mice are being used in this experiment; for each experimental group, 
n=5. There are 2 vaccination groups, 6 recipient groups, and 1 control group. The 
vaccination groups are prepared and Gene Gun vaccinated for five weeks with either WT 
HSP70i or HSP70iQ435A (in pUMVC3 DNA vector) as described in Aim I: Sub-Aim I.  
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One week after the final vaccination, these two vaccination groups were sacrificed 
and their spleens were removed for splenocyte harvest. The spleens were homogenized 
using a 70μm Nylon Mesh sterile cell strainer and washed with ice-cold HBSS; the spleen 
homogenates were pooled together according to vaccination group (product is kept on 
ice during the splenocyte harvest). ACK Lysis Buffer was used to lyse red blood cells from 
the homogenate and DNase was used to reduce clumping. Cells were washed with ice-
cold media then pelleted and resuspended in media. Cells were counted in preparation 
for sorting with MACS Separation Beads (Magnetic-Activated Cell Sorting). CD11c+ 
Dendritic Cells were sorted out first, followed by CD8+ T-Cells, and finally B220+ B cells. 
Using CD11c+ DC sorting as an example, the splenocytes were magnetically labeled with 
magnetic MicroBeads conjugated to anti-CD11c antibodies. The cell suspension is loaded 
into a column which is attached to a magnetic MACS Separator. The suspension flows 
through the column and the magnetically labeled cells are retained within the column, 
while the unlabeled cells flow through. The flow-through is kept on ice for further 
separation of CD8+ T-Cells and B220+ B cells. The column is then removed from the 
magnetic field and the magnetically labeled CD11c+ DCs are eluted through and kept on 
ice. This process is repeated using CD8 MicroBeads and B220 MicroBeads.  
At this point, there are 6 cell fractions: DCs, CD8 T-Cells, and B cells from WT 
HSP70i vaccinated mice as well as DCs, CD8 T-Cells, and B cells from HSP70iQ435A 
vaccinated mice. The cell fractions are counted, resuspended at 106 cells/100μL, and kept 
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on ice for immediate retro orbital injection into the recipient mice. The recipient mice are 
anesthetized using 5% isoflurane and receive 106 cells (Cell type is dependent upon their 
recipient group) via periorbital injection. After cell-transfer injections are complete, the 
mice were challenged with 105 B16 mouse melanoma cells, sub-cutaneously in their right 
flank. A control group of mice did not receive transferred cells, but did receive the tumor-
challenge. Tumor progression was followed as a measure of volume and, upon sacrifice, 
the tumors were harvested and weighed to measure tumor mass.  
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RESULTS 
 
                      
 
Figure 11: B cell Transfer from vaccinated to tumor-challenged mice confers tumor 
resistance. 
 
In Figure 11, a student’s T-Test revealed that tumor-challenged BL/6 mice that 
received B cells from the WT HSP70i DNA-vaccinated mice displayed a significant 75% 
decrease (p=0.016) final tumor mass when compared to the average final tumor mass 
from BL/6 mice receiving B cells from unvaccinated BL/6 mice. Tumor-challenged BL/6 
mice that received B cells from Mut HSP70i DNA-vaccinated mice also displayed a 
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significant 60% decrease (p=0.039) in final tumor mass when compared to the average 
final tumor mass from BL/6 mice receiving B cells from unvaccinated BL/6 mice (n = 7 for 
each group). 
 
Figure 12: B cell Transfer to tumor challenged SCID/Beige immunodeficient mice confers 
tumor resistance. 
 
In Figure 12, a student’s T-Test revealed a 83%  significant decrease (p=0.032) in 
average final tumor mass for the tumor-challenged SCID-beige mice that received B cells 
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from WT HSP70i DNA-vaccinated BL/6, when compared to the average final tumor mass 
from SCID-beige mice receiving no cell transfer. Tumor-challenged SCID-beige mice that 
received B cells from Mut HSP70i DNA-vaccinated BL/6 mice displayed a 90% significant 
decrease (p=0.022) in final tumor mass when compared to the average final tumor mass 
from SCID-beige mice receiving no cell transfer. Tumor-challenged SCID-beige mice that 
received B cells from unvaccinated BL/6 mice displayed a 91% significant decrease 
(p=0.021) in final tumor mass when compared to the average final tumor mass from SCID-
beige mice receiving no cell transfer (n = 5 for each group). 
 
 SUB-AIM II: Examine humoral responses to HSP70i after vaccination  
with the HSP70iQ435A clinical vector. 
 
This Sub-Aim is linked to Aim I (Sub-Aim I, Sub-Aim II, and Sub-Aim III)  and most 
of the data generated for this experimental question was analysis from harvested tissue 
and serum from these previously mentioned mouse/swine vaccination experiments and 
adoptive transfer experiments.  
EXPERIMENTAL APPROACH 
At the time of sacrifice, tissue harvesting of mouse skin and tumor were placed in 
OCT compound and snap-frozen on dry ice, spleens were harvested and homogenized, 
and a sample of blood was taken. The blood was allowed to coagulate and then spun 
down 2x to harvest serum. 
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Swine tissue was collected monthly using a 4mm Acu-Punch biopsy tool; a biopsy 
was taken from the perilesional region of the vitiligo and a second biopsy was taken from 
the contralateral flank. 50mls of swine blood was collected bi-weekly; it was allowed to 
coagulated and then spun down 2x to harvest serum.  
For immunohistological staining of tissue sections, 8 μm cryostat sectioned tissues 
were fixed in cold acetone and stored at −20 °C until use. Upon use, the tissues were 
stained using an immunohistological single stain method (using either HRP- or AP- 
conjugated antibody, and the respective detection solution) or immunofluorescence stain 
method (using fluorophore-conjugated antibody). The stained tissue sections were 
imaged on the compound microscope for immunohistological staining or fluorescent 
microscope for IF staining (at least 7 images taken per slide) and quantified. Mouse tissue 
was stained with monoclonal, PE-conjugated, hamster IgG antibody specific to the epsilon 
chain of mouse CD3. Swine tissue was stained with a primary, PE-Cy5-conjugated, mouse 
IgG1 antibody against the epsilon chain of swine CD3 from manufacturer Abcam; a 
secondary stain used PE-conjugated, polyclonal rabbit antibody against mouse IgG from 
manufacturer Dako. 
To visualize relative levels of anti-HSP70i in mouse serum after the vaccination 
experiments, purified HSP70i protein was run through an agarose gel using gel 
electrophoresis; the protein was then transferred from the gel to a PVDF membrane. 
Frozen mouse sera from the vaccination experiments outlined in Aim I: Sub-Aim I was 
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used to probe the membrane, alongside known anti-HSP70i antibodies SPA810 and 
SPA820. Dako-manufactured polyclonal, AP-conjugated Goat anti-Mouse IgG was used as 
a secondary to detect bound mouse antibody from the sera probe. AP detection solution 
was used for development of the membrane and visualization of HSP70i bound mouse 
antibody. 
Humoral responses to autologous and vaccinated HSP70i/HSP70iQ435A will be 
measured in swine sera by ELISA. To quantify levels of anti-HSP70i antibody in swine 
serum,  an anti-HSP70 ELISA kit from Enzo Life Sciences was used. Swine serum was 
applied to the HSP70-coated wells, the wells were washed, a secondary, HRP-conjugated 
Goat anti-Swine IgG antibody was and, after washing, the TMB substrate is added to 
measure concentration of HRP-conjugated secondary bound to anti-HSP70i antibody 
from swine sera. To quantify levels of HSP70i protein in the swine serum, an HSP70 high 
sensitivity ELISA kit from Enzo Life Sciences was used. Swine serum was applied to the 
wells which were coated with anti-HSP70 antibody. After washing, a primary anti-HSP70 
antibody was added, the plates are later washed, and an HRP-conjugated secondary 
antibody specific to the primary antibody is added. The plate is washed and the substrate 
is added to measure concentration of HRP-conjugated secondary bound to anti-HSP70 
primary bound to HSP70 from the swine sera.  
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RESULTS 
       
Figure 13: Vaccination with pUMVC3 vector DNA encoding HSP70i WT and HSP70iQ435A 
promotes T-Cell infiltration.  
 
In Figure 13, the CD3+ T-Cell quantification of tumor sections from the vaccination 
experiment outlined in Aim I: Sub-Aim I show a trend toward increased amounts of CD3+ 
T-Cells at the periphery of the tumors of WT HSP70i vaccinated mice (p=0.0643), with a 
50% increase in CD3+ T-Cells as compared to the quantification of CD3+ T-Cells in the 
tumor tissues from the non-vaccinated mice. A student’s T-Test revealed a significant 80% 
increase (p=0.0086) in CD3+ T-Cells at the periphery of the tumors from HSP70iQ435A 
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vaccinated mice, when compared to the quantification of CD3+ T-Cells at the periphery 
of tumor tissues from the non-vaccinated mice.  
 
 
 
Figure 14: Vaccinated mice produce more robust antibody response toward HSP70i 
when compared to unvaccinated mice. 
 
Figure 14 shows the results of a Western Blot where serum from vaccination-study 
mice (Aim I: Sub-Aim I) was used as a probing antibody against purified immunoblotted 
HSP70i protein. Known anti-HSP70 antibodies, SPA-810 and SPA-820, were included as 
positive controls. When compared to the mice that were not vaccinated, the sera from 
vaccinated mice seem to contain a very robust antibody response toward HSP70i, around 
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a 400% increase in band density as measured in ImageJ; this was seen most in the sera 
taken from mice vaccinated with HSP70i in pUMVC3 vector. 
 
 
Figure 15: Treatment with DNA-vaccine encoding HSP70iQ435A can inhibit CD3+ T cell 
infiltration in lesional vitiligo skin. 
 
Swine CD3+ T cells were quantified and measured as CD3+ T cells/mm2 of the 
biopsy area; as we took monthly biopsies, this allowed us follow changes over time in the 
CD3+ T cell count at the periphery of the lesional areas, as represented in Figure 15. The 
DNA treated swine from Group #1 exhibits a significant 83% decrease (p=0.007) in CD3+ 
T cell counts between weeks 4 and 8, which coincides with the end of its DNA treatments. 
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The CD3+ T cell count slowly begins to rise but plateaus at around 30 CD3+ T cells/mm2 
and does not rise back to original levels observed in the first week [15a]. The PBS treated 
swine from Group #1 does not display any major increases or decreases in CD3+ T cell 
counts at the periphery of its melanoma lesional area over the course of 24 weeks [15b]. 
The DNA treated swine from Group #2 does not display significant changes while the CD3+ 
T cell counts of the PBS treated swine from group #2 steadily climbs over the course of 20 
weeks [15c-d].  
 
 
 
Figure 16: Treatment with DNA-vaccine encoding HSP70iQ435A can inhibit CD3+ T cell 
infiltration in lesional vitiligo skin over time. 
 
 
 
Figure 16 displays the data from Swine Group #2 as the average CD3+ T cell counts 
of each respective treatment with each week represented as fold change from Week 0. 
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Figure 17: HSP70i DNA-treatment in pigs can produce an antibody response toward 
HSP70i.  
 
Through an ELISA using sera taken from the swine, it was revealed that the DNA 
treated swine from Group #2 produced a significant, 300% increase in anti-HSP70i 
antibody between the first week of treatment and the fourth and final week of treatment; 
that elevated level of antibody remained into week 6, and began dropping back to basal 
levels around week 8 as seen in Figure 17. The remaining swine did not display any 
significant changes in anti-HSP70i antibody concentration.  
 
 
 
37 
 
 
 
 
Figure 18: HSP70i DNA-treatment in swine can raise serum levels of HSP70i protein 
beyond basal levels.  
 
Figure 18 shows the results of an ELISA run with sera taken from the swine to 
detect serum level HSP70i protein in the swine vaccinated with HSP70iQ435A DNA vaccine. 
It was revealed that the DNA treated swine from Group #2 produced a significant increase 
(p=0.0003) in serum HSP70i protein between week 4 and week 8, which then dropped 
back down to basal levels by week 12. The remaining swine did not display any significant 
changes in serum HSP70i protein concentration.   
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CHAPTER 4 
DISCUSSION 
Because HSP70iQ435A inhibits the T cell-mediated auto-immune response against 
melanocytes in vitiligo mouse models, there existed a valid concern that treatment with 
this modified heat shock protein may also inhibit natural responses against melanocyte-
derived melanoma tumor cells. As such, the first part of this project was to study the 
effects of HSP70iQ435A DNA-treatment in a mouse melanoma model. The results from 
these first two mouse studies indicated that not only was HSP70iQ435A not inhibitory of 
anti-melanoma responses in mice, but DNA-treatment with both WT HSP70i and 
HSP70iQ435A confer some degree of tumor resistance [Figure 1-3]. Regarding HSP70iQ435A 
as a therapeutic agent for vitiligo treatment, these results are promising; vitiligo therapy 
would be a step in the wrong direction if it decreased the patient’s immune response to 
melanoma. This is especially relevant considering vitiligo is oftentimes a side-effect of 
melanoma therapy as treatments targeting melanoma cells also collaterally target 
melanocytes; as a result, vitiligo during melanoma therapy is sometimes considered a 
good sign that the treatment is working (17). Staining results from these initial 
experiments also show increased CD3 T cell counts around the periphery of the 
melanoma tumor from mice that received either the WT HSP70i DNA-vaccination or the 
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HSP70iQ435A when compared to the mice that received no treatment [Figure 13]. This is 
compared to previous studies which observed decreased T cell infiltration in healthy and 
vitiligo-affected skin after mice were vaccinated with HSP70iQ435A (Reference 4, Figure 3). 
These results suggest that DNA-treatment with HSP70iQ435A can promote T cell presence 
at the melanoma, while decreasing T cell presence at lesional vitiligo skin. Taken together, 
this information seems to imply separate mechanisms by which HSP70iQ435A DNA-
treatment might be inhibiting the auto-immune response against melanocytes and 
promoting the anti-tumor response to melanoma.  
Knowing that melanoma and other tumor cells overexpress and externally present 
stress induced heat shock proteins such as HSP70i (7), we wanted to test the antibody 
response to purified HSP70i protein after vaccination with either the WT HSP70i or 
HSP70iQ435A. After running a Western with purified HSP70i and probing with sera 
harvested from the mice in the previous experiments outline in Aim I: Sub-Aim I, the 
results suggested that a DNA-treatment with WT HSP70i and HSP70iQ435A can promote 
production of antibody against HSP70i and as such may be promoting anti-melanoma 
responses via antibody-dependent cell-mediated cytoxicity (ADCC). Previous studies have 
targeted membrane-bound HSP70 as a means of inducing ADCC killing of tumor cells, 
where tumor growth was reduced in mice treated with antibody specific to an HSP70 
epitope frequently detected on the surface of tumor cells (18). Results from the adoptive 
transfer experiment outlined in Aim II: Sub-Aim I seem to coincide with those studies and 
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suggest that antibody-mediation may indeed be the cause of this tumor inhibition. Tumor 
challenged BL/6 mice that received B cells from HSP70i DNA-vaccinated BL/6 mice 
displayed markedly smaller tumors, suggesting the B cell transfer was responsible for the 
tumor inhibition [Figure 11]. To further test this, B cells taken from vaccinated BL/6 mice 
were adoptively transferred into tumor-challenged, immuno-deficient SCID-beige mice. 
Strangely, however, results showed decreased tumor growth in all mice that received B 
cell injections, even the mice that received no HSP70i DNA-treatment [Figure 12]; 
however, there was no significance between the vaccinated and unvaccinated tumors. 
Considering that SCID-beige strain is immuno-deficient of B and T cells, while still 
containing defective NK cells, it might be possible that antibody from these adoptively 
transferred B cells may still be enough to activate the NK cells in SCID-beige mice 
(although this does not explain why the adoptive transfers from non-vaccinated mice are 
doing so). Adoptive transfers of sensitized and primed B cells have previously been shown 
to promote humoral anti-tumor responses in mice, where the adoptive transfer resulted 
in production of tumor-specific antibody and tumor cell lysis in the presence of 
complement (19). As SCID-beige mice contain normal complement levels, it is likely that 
complement-dependent cytotoxic killing of tumor cells played a role in both of the 
adoptive transfers.  
A separate vaccination and tumor challenge experiment was also done on PMEL-
1 mice. These mice were chosen as they have transgenic T cell receptors specific to the 
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mouse homologue (pmel-17) of human gp100, a melanocytic protein involved in pigment 
synthesis. They naturally depigment which makes this strain a good choice for a vitiligo 
mouse model; however it can take up to several months for any natural depigmentation 
to occur. For this reason, the mice used in Aim I: sub-aim II were also vaccinated with the 
DNA encoding gp100 to facilitate and speed up the depigmentation, alongside either the 
WT HSP70i DNA and HSP70iQ435A DNA. Results from the tumor growth and final tumor 
mass once again suggest anti-tumor responses mediated by treatment with an HSP70i 
DNA-vaccine are not affected by the Q435A mutation in the stress protein [Figure 6, Figure 
5]. As for the depigmentation results, mice treated with DNA encoding HSP70iQ435A display 
slightly decreased average depigmentation at the end of the experiment when compared 
to mice treated with DNA encoding WT HSP70i [Figure 7, Figure 8]. These data don’t quite 
coincide with data from previous depigmentation studies, where the depigmentation was 
significantly decreased in mice treated with DNA encoding HSP70iQ435A; it’s likely that the 
addition of DNA encoding gp100 during the gene-gun vaccinations may have caused this 
inconsistency and largely overruled the dampening effects of HSP70iQ435A, facilitating 
depigmentation a lot more than we originally bargained for. Future studies will likely omit 
or reduce the gp100 treatment, assuming that time is not a constraint as it was during 
this study.  Additionally, this study where treatment with gp100 is done alongside 
HSP70iQ435A may prove useful in future trials related to gp100 treatment; as clinical trials 
have already demonstrated gp100 as a successful melanoma antigen to target for 
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melanoma therapy (20, 21) there will likely be a demand for secondary or additional 
primary treatments to deter the vitiligo that develops as a result of the patient’s immune 
system targeting melanocytic gp100.  
To set the stage for further developments of HSP70iQ435A as a treatment for 
autoimmune side effects of melanoma immunotherapy, we chose to test the efficacy of 
these treatments on a swine model of vitiligo. This substrain of Sinclair miniature swine 
is unique in that the swine spontaneously develop melanoma at a young age and, as the 
melanoma regresses, they develop vitiligo as a side-effect (usually seen as a ring of 
depigmented skin around the regressing melanoma). It should also be noted that 2 out of 
the 4 swine that were sent to us did not have visible lesions of vitiligo which complicated 
things in terms of analyzing the results. We used the DNA treatment on the 2 swine that 
had visible vitiligo, and the PBS control treatment on the two swine that did not have 
visible vitiligo (PBS injections were performed at a site of melanoma on these 2 swine). 
The data seems to indicate a positive response from the DNA treatment in the first swine 
[Figures 15a, 17a, 18ab] while there was not as much of a response in the second DNA 
treated swine [Figures 15c, 17c, 18cd]. However, we must also consider that any area of 
regressing vitiligo would see increasing levels of infiltrating T cells, and the maintenance 
of a steady level in DNA Swine #2 may be indicative of a positive response to the 
treatment. These swine are incredibly diverse when compared to a strain of lab mouse, 
and variation in response to any experimental treatment is not unexpected. However, it 
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is very promising to see the treatment working the way it is meant to be working in the 
first DNA treated pig, and watching the T cell counts around the lesion decrease as the 
lesion itself decreases in size and begins to repigment. Furthermore, one of the 
milestones we had set for the trial included a 50% reduction in T cell infiltration which 
was observed in the Group #1 swine treated with DNA, with a 75% decrease in CD3+ T 
cells between the first week and the eight week; even comparing the first week with the 
final week, there is still a 58% decrease [Figure 15a]. The data from the two ELISAs [Figures 
17, 18] seems to suggest that the second swine did respond but in a different manner 
than the first swine; where the first swine managed to divert the cytotoxic response away 
from the treated area, the second swine began producing antibody against HSP70i. 
Unfortunately, it’s still too early to judge what effect this might have on the swine’s anti-
melanoma responses but it will definitely be interesting to follow.  
Conclusive Remarks 
The results from these studies support the ongoing development of a novel 
therapeutic that not only has the ability to restrict with the autoimmune responses that 
cause vitiligo, but also maintain anti-tumor responses at the same time. Treatment with 
HSP70iQ435A helps inhibit the cytotoxic auto-immune response against healthy 
melanocytes, does not interfere with anti-tumor responses to melanoma cells, and also 
seems to support anti-melanoma responses by stimulating production of anti-HSP70i 
antibody which are able to direct antibody dependent cell-mediated cytotoxic responses 
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against the HSP70i-saturated melanoma cells; these mechanisms are summarized in 
Figure 19.  
 
Figure 19: Mutant HSP70iQ435A promotes anti-tumor immunity while preventing auto-
immunity. 
 
(1) In vitiligo, stress to healthy melanocytes induces synthesis of HSP70i which is 
(2) secreted from live cells through an active-release mechanism. These secreted HSP70i 
proteins can potentially be chaperoning misfolded melanocytic proteins that are in the 
process of refolding within the cell and, once in the extracellular environment, (3) bind to 
and activate local dendritic cells to an inflammatory phenotype. These dendritic cells 
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move through the draining lymph nodes where they (4) present melanocyte antigen to T 
cells and stimulate a (5) melanosomal-ag specific CD8+ T cell cytotoxic response that 
results in melanocyte destruction and depigmentation characteristic of vitiligo. When 
HSP70iQ435A is introduced to the early steps of the system, a single amino acid change 
(Glutamine to Alanine) in the DC-binding region of HSP70i is sufficient to deter (3) DC 
activation to an inflammatory phenotype, instead inducing a non-inflammatory 
phenotype which do not process and present melanocyte antigen. B cells in the lymph 
are presented with DC-bound HSP70i and, upon recognition, proliferate and produce 
HSP70i-specific antibody. (6) These antibodies recognize and bind surface HSP70i on 
melanoma cells; CD16+ natural killer cells then bind the Fc region of the antibody, 
stimulating the NK cell to release perforin, forming lytic pores in the melanoma, and 
granzyme to induce apoptosis in the targeted melanoma cell. 
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